Leukemic stem cells hijack lineage inappropriate signalling pathways to promote their growth

Acute Myeloid Leukemia (AML) is caused by multiple mutations which dysregulate growth and differentiation of myeloid cells. Cells adopt different gene regulatory networks specific to individual mutations, maintaining a rapidly proliferating blast cell population with fatal consequences for the patient if not treated. The most common treatment option is still chemotherapy which targets such cells. However, patients harbour a population of quiescent leukemic stem cells (LSCs) which can emerge from quiescence to trigger relapse after therapy. The processes that allow such cells to re- grow remain unknown. Here, we examined the well characterised t(8;21) AML sub-type as a model to address this question. Using a novel t(8;21) patient-derived xenograft model, we show that t(8;21) LSCs aberrantly activate the VEGF and IL-5 signalling pathways. Both pathways operate within a regulatory circuit consisting of the driver oncoprotein RUNX1::ETO and an AP-1/GATA2 axis allowing LSCs to re-enter the cell cycle while preserving self-renewal capacity.

[1]  Qianghu Wang,et al.  Single-cell analysis reveals the chemotherapy-induced cellular reprogramming and novel therapeutic targets in relapsed/refractory acute myeloid leukemia , 2022, Leukemia.

[2]  Salam A. Assi,et al.  Identification and interrogation of the gene regulatory network of CEBPA-double mutant acute myeloid leukemia , 2022, Leukemia.

[3]  J. Broach,et al.  Subtype-specific 3D genome alteration in acute myeloid leukaemia , 2022, Nature.

[4]  M. Heuser,et al.  Nanoparticle-mediated targeting of the fusion gene RUNX1/ETO in t(8;21)-positive acute myeloid leukaemia , 2022, bioRxiv.

[5]  J. Coxhead,et al.  hiPSC-derived bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukemia , 2022, Cell reports. Medicine.

[6]  P. A. Futreal,et al.  A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia , 2022, Nature Medicine.

[7]  A. Salomon,et al.  H3K27me3 conditions chemotolerance in triple-negative breast cancer , 2022, Nature Genetics.

[8]  L. Bullinger,et al.  Longitudinal single-cell transcriptomics reveals distinct patterns of recurrence in acute myeloid leukemia , 2022, Molecular Cancer.

[9]  Salam A. Assi,et al.  PLCG1 is required for AML1-ETO leukemia stem cell self-renewal. , 2021, Blood.

[10]  Raja Jothi,et al.  Decoding the function of bivalent chromatin in development and cancer , 2021, Genome research.

[11]  Sandra Pinho,et al.  Leukemic Stem Cells: From Leukemic Niche Biology to Treatment Opportunities , 2021, Frontiers in Immunology.

[12]  E. Wagner,et al.  JunB is a key regulator of multiple myeloma bone marrow angiogenesis , 2021, Leukemia.

[13]  E. Szegezdi,et al.  Hematopoietic versus leukemic stem cell quiescence: Challenges and therapeutic opportunities. , 2021, Blood reviews.

[14]  Raphael Gottardo,et al.  Integrated analysis of multimodal single-cell data , 2020, Cell.

[15]  K. Regha,et al.  Different mutant RUNX1 oncoproteins program alternate haematopoietic differentiation trajectories , 2020, Life Science Alliance.

[16]  A. Akalin.  RNA-seq Analysis , 2020, Computational Genomics with R.

[17]  E. Stanley,et al.  Expression of RUNX1-ETO Rapidly Alters the Chromatin Landscape and Growth of Early Human Myeloid Precursor Cells , 2020, Cell reports.

[18]  J. Licht,et al.  FOXM1 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML , 2020, Nature Communications.

[19]  K. Sachs,et al.  Single-cell gene expression analyses reveal distinct self-renewing and proliferating subsets in the leukemia stem cell compartment in acute myeloid leukemia. , 2019, Cancer research.

[20]  Cameron S. Osborne,et al.  RUNX1-ETO Depletion in t(8;21) AML Leads to C/EBPα- and AP-1-Mediated Alterations in Enhancer-Promoter Interaction , 2019, Cell reports.

[21]  Cameron S. Osborne,et al.  RUNX1-ETO Depletion in t(8;21) AML Leads to C/EBPα- and AP-1-Mediated Alterations in Enhancer-Promoter Interaction , 2019, Cell reports.

[22]  S. Edkins,et al.  Gata2 as a Crucial Regulator of Stem Cells in Adult Hematopoiesis and Acute Myeloid Leukemia , 2019, Stem cell reports.

[23]  Steven L Salzberg,et al.  Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype , 2019, Nature Biotechnology.

[24]  Supat Thongjuea,et al.  Cell-intrinsic depletion of Aml1-ETO-expressing pre-leukemic hematopoietic stem cells by K-Ras activating mutation , 2019, Haematologica.

[25]  G. Pinkus,et al.  Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity , 2019, Cell.

[26]  Andrew J. Hill,et al.  The single cell transcriptional landscape of mammalian organogenesis , 2019, Nature.

[27]  Salam A. Assi,et al.  The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation , 2018, Cancer cell.

[28]  B. Leber,et al.  Identification of Chemotherapy-Induced Leukemic-Regenerating Cells Reveals a Transient Vulnerability of Human AML Recurrence. , 2018, Cancer cell.

[29]  Salam A. Assi,et al.  Subtype-specific regulatory network rewiring in acute myeloid leukemia , 2018, Nature Genetics.

[30]  S. Haas,et al.  Causes and Consequences of Hematopoietic Stem Cell Heterogeneity. , 2018, Cell stem cell.

[31]  Catriona McLean,et al.  Inhibition of Endosteal Vascular Niche Remodeling Rescues Hematopoietic Stem Cell Loss in AML , 2018, Cell stem cell.

[32]  Nicholas A. Sinnott-Armstrong,et al.  An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues , 2017, Nature Methods.

[33]  Howard Y. Chang,et al.  Lineage-specific and single cell chromatin accessibility charts human hematopoiesis and leukemia evolution , 2016, Nature Genetics.

[34]  Fidel Ramírez,et al.  deepTools2: a next generation web server for deep-sequencing data analysis , 2016, Nucleic Acids Res..

[35]  H. Maecker,et al.  Platinum‐conjugated antibodies for application in mass cytometry , 2016, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[36]  R. Flavell,et al.  inv(16) and NPM1mut AMLs engraft human cytokine knock-in mice. , 2016, Blood.

[37]  Salam A. Assi,et al.  Developmental-stage-dependent transcriptional response to leukaemic oncogene expression , 2015, Nature Communications.

[38]  S. Salzberg,et al.  StringTie enables improved reconstruction of a transcriptome from RNA-seq reads , 2015, Nature Biotechnology.

[39]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[40]  R. Henschler,et al.  Activating c-KIT mutations confer oncogenic cooperativity and rescue RUNX1/ETO-induced DNA damage and apoptosis in human primary CD34+ hematopoietic progenitors , 2014, Leukemia.

[41]  Salam A. Assi,et al.  Identification of a Dynamic Core Transcriptional Network in t(8;21) AML that Regulates Differentiation Block and Self-Renewal , 2014, Cell reports.

[42]  T. Enver,et al.  Leukemia propagating cells rebuild an evolving niche in response to therapy. , 2014, Cancer cell.

[43]  Björn Usadel,et al.  Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..

[44]  Jeffrey A. Magee,et al.  Haematopoietic stem cells require a highly regulated protein synthesis rate , 2014, Nature.

[45]  Wei Shi,et al.  featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..

[46]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[47]  A. Tanay,et al.  Addiction of t(8;21) and inv(16) acute myeloid leukemia to native RUNX1. , 2013, Cell reports.

[48]  H. Gabra,et al.  Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells , 2013, Oncogene.

[49]  E. Vellenga,et al.  Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK). , 2012, Blood.

[50]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[51]  Salam A. Assi,et al.  Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding , 2012, Leukemia.

[52]  Angelo J. Canty,et al.  Stem cell gene expression programs influence clinical outcome in human leukemia , 2011, Nature Medicine.

[53]  Emery H. Bresnick,et al.  Genetic framework for GATA factor function in vascular biology , 2011, Proceedings of the National Academy of Sciences.

[54]  W. Kamps,et al.  Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia. , 2011, Cancer research.

[55]  P. Vyas,et al.  Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. , 2011, Cancer cell.

[56]  C. Mackay,et al.  MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. , 2010, The Journal of allergy and clinical immunology.

[57]  C. Glass,et al.  Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. , 2010, Molecular cell.

[58]  G. Follows,et al.  Aberrant expression of CD19 in AML with t(8;21) involves a poised chromatin structure and PAX5 , 2010, Oncogene.

[59]  T. Lister,et al.  AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia. , 2010, Cancer research.

[60]  Aaron R. Quinlan,et al.  Bioinformatics Applications Note Genome Analysis Bedtools: a Flexible Suite of Utilities for Comparing Genomic Features , 2022 .

[61]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[62]  E. Passegué,et al.  JunB protects against myeloid malignancies by limiting hematopoietic stem cell proliferation and differentiation without affecting self-renewal. , 2009, Cancer cell.

[63]  Tariq Enver,et al.  High GATA-2 expression inhibits human hematopoietic stem and progenitor cell function by effects on cell cycle. , 2009, Blood.

[64]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[65]  J. Keefer,et al.  C/EBP alpha:AP-1 leucine zipper heterodimers bind novel DNA elements, activate the PU.1 promoter and direct monocyte lineage commitment more potently than C/EBP alpha homodimers or AP-1. , 2008, Oncogene.

[66]  Dustin E. Schones,et al.  High-Resolution Profiling of Histone Methylations in the Human Genome , 2007, Cell.

[67]  A. Bert,et al.  A Modular Enhancer Is Differentially Regulated by GATA and NFAT Elements That Direct Different Tissue-Specific Patterns of Nucleosome Positioning and Inducible Chromatin Remodeling , 2007, Molecular and Cellular Biology.

[68]  M. Shikami,et al.  t(8;21) acute myeloid leukaemia cells are dependent on vascular endothelial growth factor (VEGF)/VEGF receptor type2 pathway and phosphorylation of Akt , 2006, British journal of haematology.

[69]  T. Lister,et al.  AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. , 2006, Blood.

[70]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[71]  S. Nishikawa,et al.  Involvement of Runx1 in the down-regulation of fetal liver kinase-1 expression during transition of endothelial cells to hematopoietic cells. , 2005, Blood.

[72]  C. Bloomfield,et al.  Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  R. Mulligan,et al.  Efficiency of transduction of highly purified murine hematopoietic stem cells by lentiviral and oncoretroviral vectors under conditions of minimal in vitro manipulation. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[74]  A. Persson,et al.  The Leukemia-associated ETO homologues are differently expressed during hematopoietic differentiation. , 2005, Experimental hematology.

[75]  E. Wagner,et al.  AP-1: a double-edged sword in tumorigenesis , 2003, Nature Reviews Cancer.

[76]  D. Tenen,et al.  The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner , 2003, Oncogene.

[77]  D. Tenen,et al.  The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. , 2003, Blood.

[78]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[79]  Torsten Haferlach,et al.  AML1–ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia , 2001, Nature Medicine.

[80]  A. Jakubowiak,et al.  The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1 , 1999, Oncogene.

[81]  Leonard,et al.  Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.

[82]  M. Olive,et al.  A Dominant Negative to Activation Protein-1 (AP1) That Abolishes DNA Binding and Inhibits Oncogenesis* , 1997, The Journal of Biological Chemistry.

[83]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[84]  M. Caligiuri,et al.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.

[85]  G. Jiménez,et al.  Activation of the beta-globin locus control region precedes commitment to the erythroid lineage. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[86]  Anthony C. Willis,et al.  Rapid histone H3 phosphorylation in response to growth factors, phorbol esters, okadaic acid, and protein synthesis inhibitors , 1991, Cell.

[87]  N. Kamada,et al.  Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. , 1991, Blood.

[88]  Richard Treisman,et al.  Identification of a protein-binding site that mediates transcriptional response of the c-fos gene to serum factors , 1986, Cell.